Subjective Analgesic Effects of Naloxone and Virtual Reality
This trial is active, not recruiting.
|Sponsor||University of Washington|
|Start date||August 2010|
|End date||June 2014|
|Trial size||50 participants|
|Trial identifier||NCT01105871, 35974-D|
This study is designed to test a specific hypothesis exploring the neurophysiologic mechanism(s) that underlie the pain- relieving effects of immersive Virtual Reality (VR) as a non-pharmacologic pain management technique, using healthy volunteers experiencing carefully controlled thermal and/or electrical pain in the laboratory. Over the past decade, our research group has performed a series of NIH-funded investigations of VR analgesia - in both the clinical pain and laboratory pain settings - demonstrating its clinical efficacy and safety. In the current study we will test pharmacologic manipulation of VR analgesia (with the opioid analgesia antagonist naloxone). We anticipate that this theoretical work will provide a foundation for future clinical applications of immersive VR - whether used alone or in combination with other analgesic agents - and make immersive VR a more effective and more widely used analgesic tool for the treatment of clinical pain.
Our previous work with immersive VR indicates that its use during a painful event can reduce subjective pain reports during both acute clinical and laboratory pain by 20-50% . Furthermore, we have shown that effective VR analgesia is associated with reduced pain-related brain activity that is quantitatively and qualitatively comparable to clinically relevant doses of systemic opioid analgesics . The laboratory pain protocol proposed in the current application is identical to the UW HSD-approved protocol used in our previous studies (#25296 - "Reducing Brief Thermal and Electrical Pain"). What is specifically different in the current protocol is the use of naloxone to determine whether VR analgesia operates through an endogenous opioid-dependent mechanism or not. The results of this study will not only suggest the mechanism of action of VR analgesia, but also allow us to more effectively apply immersive VR analgesia in the clinically pain setting through its thoughtful combination with well-established pharmacologic analgesic techniques, such as opioid analgesia administration.
The specific aim of this study and the hypothesis it tests are as follows: To determine the extent to which subjective analgesic effects of VR analgesia are inhibited by opioid receptor antagonism with naloxone. Hypothesis - VR analgesia will not be inhibited by systemic opioid receptor antagonism, suggesting that VR analgesia is not mediated by release of endogenous opiates and/or by activation of opioid-dependent descending central nervous system pathways.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
|Masking||double blind (subject, investigator)|
|Primary purpose||supportive care|
4 mg in 10 ml saline iv bolus
10 ml of normal saline iv bolus
Pain scoring from sessions where naloxone is given or placebo.Pain scoring is a questionnaire using analog scale (1-10).
time frame: Outcome measurements will be assessed when all research and analysis has been completed. We project the approximate time frame to be about 18 months.
Male or female participants from 18 years up to 60 years old.
Inclusion Criteria: - Healthy males and females between the ages of 18 and 60 years - Ability to communicate orally - Body mass index of 30 or less Exclusion Criteria: - Women who are pregnant, trying to become pregnant or who are breastfeeding. - History of alcohol or substance abuse - Major medical illness, including history or migraine headaches - Allergy or sensitivity to narcotics or naloxone - Current use of analgesics including acetaminophen, non-steroidal anti-inflammatories, or opioids - Predisposition to severe motion sickness - Unusual sensitivity or lack of sensitivity to pain - Sensitive skin - Urine toxicology positive for opioids
|Official title||Subjective Analgesic Effects of Naloxone and Virtual Reality|
|Principal investigator||Samuel R Sharar, MD|
Call for more information